Sanofi to cut U.S. insulin costs for some patients to $99 per month
from U.S. News & World Report
Sanofi SA said on Wednesday it will cut the cost of its insulin products to $99 per month for uninsured patients and others who pay cash for it in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication. Sanofi announced the plan hours before one of its executives was set to testify before a congressional committee on the rising prices of insulin. Executives from the other leading insulin producers — Eli Lilly & Co and Novo Nordisk A/S — will also testify.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063